<< Back | Health News Home
PPIs and Increased Risk of COVID

On July 7th, 2020, The American Journal of Gastroenterology reported that the use of PPIs appears to increase the risk of COVID-19. Proton Pump Inhibitors are commonly used to reduce stomach acid and relieve symptoms of gastric reflux. A survey of 53,130 adult Americans found that there is a dose-response relationship between the amount of acid suppression and the risk of COVID-19. Compared to those not using PPIs, those taking twice-daily PPIs had a 3.7-fold increased risk of COVID-19. In contrast, people taking less powerful drugs to suppress acid production, such as famotidine or cimetidine, were not at increased risk for COVID-19. Clinicians should consider whether twice-daily PPI dosing is necessary for individual patients, particularly those who are especially vulnerable for severe COVID-19 and if famotidine or cimetidine may be considered as an alternative treatment. 

References

https://webfiles.gi.org/links/media/ACG_Almario_et_al_Info_Sheet_and_FAQs_About_PPIs_COVID19_07072020_FINAL.pdf


Copyright © 2007 - 2020, Storey Marketing. All rights reserved.